A phase IIb study of selinexor in combination with daratumumab in patients with daratumumab-refractory multiple myeloma.

ABSTRACT:

SUBMITTER: Biran N 

PROVIDER: S-EPMC12485305 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature